Retrospective analysis of randomized phase II trial (WJOG6210G) of FOLFIRI with either panitumumab or bevacizumab as second-line treatment in patients with KRAS wild metastatic colorectal cancer refractory to oxaliplatin and bevacizumab to evaluate the association of survival time and treatment efficacy (early tumor shrinkage, depth of response and best overall response) at each arm

Retrospective analysis of randomized phase II trial (WJOG6210G) of FOLFIRI with either panitumumab or bevacizumab as second-line treatment in patients with KRAS wild metastatic colorectal cancer refractory to oxaliplatin and bevacizumab to evaluate the association of survival time and treatment efficacy (early tumor shrinkage, depth of response and best overall response) at each arm - Retrospective analysis for predictive factor of FOLFIRI+Pmab vs FOLFIRI+BV as second-line for colorectal cancer

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000031621

Enrollment

117

Registered

2018-03-07

Start date

2018-04-12

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Colorectal cancer

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients who were enrolled in WJOG6210G study

Exclusion criteria

Exclusion criteria: None

Design outcomes

Primary

Measure	Time frame
To evaluate the association of survival time (progression-free survival, overall survival) and treatment efficacy (early tumor shrinkage, depth of response and best overall response) at each arm (FOLFIRI+BV, FOLFIRI+Pmab) for metastatic colorectal cancer as second-line chemotherapy.	—

Secondary

Measure	Time frame
To evaluate the association of known data of ligand protein level and period of BV treatment during first-line chemotherapy. To evaluate the association of treatment efficacy and patient characteristics. To evaluate the association of survival time and patient characteristics. To evaluate the association of survival time and known data of ligand protein level. To evaluate the association of survival time and VEGF-D which is measured by using residual sample, treatment efficacy and VEGF-D, and patient characteristics and VEGF-D.	—

Measure

Time frame

To evaluate the association of known data of ligand protein level and period of BV treatment during first-line chemotherapy. To evaluate the association of treatment efficacy and patient characteristics. To evaluate the association of survival time and patient characteristics. To evaluate the association of survival time and known data of ligand protein level. To evaluate the association of survival time and VEGF-D which is measured by using residual sample, treatment efficacy and VEGF-D, and patient characteristics and VEGF-D.

—

Countries

Japan

Contacts

Public ContactShinichiro Nakamura

West Japan Oncology Group WJOG datacenter

datacenter@wjog.jp06-6633-7400

Outcome results